Atorvastatin for reduction of 28-day mortality in severe and critical COVID-19 patients: a randomized controlled trial

Table 3 Bivariate and multivariable analyses of Atorvastatin use and 28-day mortality or 6-month mortality

Independent factors	Bivariate at 28-day mortality		Multivariable model at 28-day mortality		Bivariate at 6-month mortality		Multivariable model at 6-month mortality
Independent factors	Unadjusted OR (95% CI)	P value	Adjusted OR (95% CI)	P value	Unadjusted OR (95% CI)	P value	Adjusted OR (95% CI)	P value
Atorvastatin	0.907 (0.526, 1.565)	0.727	0.773 (0.407, 1.47)	0.433	0.697 (0.397, 1.223)	0.208	0.573 (0.293, 1.117)	0.102
Age	1.065 (1.037, 1.094)	< 0.001*	1.078 (1.046, 1.11)	< 0.001*	1.061 (1.033, 1.09)	< 0.001*	1.077 (1.044, 1.11)	< 0.001*
Male	1.862 (1.043, 3.325)	0.036*	1.881 (0.978, 3.618)	0.058	1.569 (0.864, 2.849)	0.139	2.185 (1.104, 4.324)	0.025*
No. of comorbidities	1.076 (0.801, 1.444)	0.627	0.856 (.605, 1.212)	0.382	1.078 (0.794, 1.464)	0.629	0.802 (0.557, 1.154)	0.234
Critical cases	0.082 (0.024, 0.278)	< 0.001*	14.343 (4.263, 48.252)	< .001*	17.5 (4.062, 75.388)	< 0.001*	17.903 (4.516, 70.979)	< 0.001*

OR: odds ratio; CI: confidence interval. No. of comorbidities includes (Diabetes mellitus, hypertension, ischemic heart disease, AF, Chronic obstructive pulmonary disease)
^*P ≤ 0.05 indicated Statistical significance. The constant of the 28-day mortality model is − 4.855, while the constant of the 6-month mortality model is − 4.456

ISSN: 1465-993X